Jul 31, 2024
Immutep Quarterly Activities Report Q4 FY24
Jul 21, 2024
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Jul 17, 2024
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
Jul 11, 2024
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Jul 03, 2024
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
